Slipped Capital Femoral Epiphysis as a Complication of Growth Hormone Therapy

Wang, Shuo-Yu; Tung, Yi‐Ching; Tsai, Wen-Yu; Chien, Yin‐Hsiu; Lee, Jing-Sheng; Hwu, Wuh‐Liang

doi:10.1016/s0929-6646(09)60352-1

Cited by 12 publications

(18 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11) The causes of SCFE have not been identified, although hormonal disorders including hypothyroidism, hyperparathyroidism, hypogonadism, gigantism and obesity, and rhGH treatment are known to be related to this disorder. 12,13) Several studies of the relationship between SCFE and GnRHa treatment have been published. 11,13) We treated the the younger sister described here with a concurrent, GnRHa and rhGH therapy.…”

Section: A C C E P T E D a R T I C L Ementioning

confidence: 99%

Central precocious puberty with hypothalamic hamartoma: the first case reports of 2 siblings with different phenotypes of Seckel syndrome 5

Park¹,

Jeon²,

Maeng³

et al. 2023

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

Hypothalamic hamartomas (HHs) are non-neoplastic mass lesions located in the hypothalamus that presented with central precocious puberty (CPP), and/or gelastic seizures. Seckel syndrome (OMIM210600, SCKL) is a rare autosomal recessive genetic spectrum disorder characterized by intrauterine growth retardation, proportionate osteodysplastic primordial dwarfism, a wide range of intellectual disability, "bird-headed" facial features and microcephaly with various brain structural abnormalities. Two siblings presented with a short stature with small head circumference and diagnosed SCKL 5. Interestingly, the younger sister had HH with CPP and a slipped capital femoral epiphysis during treatment. Herein, we report that the two siblings with the same genetic variant showed different phenotypes, which have not been reported previously as the first cases of SCKL diagnosed by genetic confirmation in Korea.

show abstract

Section: A C C E P T E D a R T I C L Ementioning

confidence: 99%

Central precocious puberty with hypothalamic hamartoma: the first case reports of 2 siblings with different phenotypes of Seckel syndrome 5

Park¹,

Jeon²,

Maeng³

et al. 2023

Ann Pediatr Endocrinol Metab

View full text Add to dashboard Cite

show abstract

“…For example, GH therapy can be causing some serious but uncommon side effects such as increased intracranial pressure, slipped capital femoral epiphysis (SCFE), impaired glucose tolerance, hypothyroidism, and gynecomastia. 1,2 Indeed, there is an increased prevalence of SCFE in children treated with GH. 2 SCFE is the most common hip disorder in children aged between 9 and 15 years.…”

Section: Introductionmentioning

confidence: 99%

“…1,2 Indeed, there is an increased prevalence of SCFE in children treated with GH. 2 SCFE is the most common hip disorder in children aged between 9 and 15 years. 3 SCFE is a slippage and separation of the metaphysis from the epiphysis of the proximal femur.…”

Section: Introductionmentioning

confidence: 99%

Slipped Capital Femoral Epiphysis after 2 Months from Starting Growth Hormone Therapy

Abdullah,

Alsaffar

2023

Journal of Diabetes and Endocrine Practice

View full text Add to dashboard Cite

Recombinant growth hormone (GH) is a widely used hormonal therapy for children and adolescents with GH deficiency or short stature related to certain conditions. Generally, GH therapy has a good safety profile; however, it could have rare but significant orthopaedic complications including slipped capital femoral epiphysis (SCFE). Pediatric endocrinologists are aware of these possible complications, and they are responsible for appropriately counseling their patients before commencing this hormone. However, the pediatric endocrinologist may not be the first clinician who encounters the orthopaedic complications of GH, as the patient may seek an emergency medical opinion from people from other specialties. Here, we report the case of a 13-year-old Iraqi adolescent boy who presented with limping that appeared only 2 months after receiving GH (0.035 mg/kg/d). He was diagnosed with SCFE in a relatively very short time after commencement of the treatment. Despite this, the patient was not considered to be at high risk of SCFE. A careful evaluation of SCFE in patients complaining of a limp or hip and knee pain during GH therapy is highly recommended.

show abstract

“…In non-GH deficient conditions, including skeletal dysplasias, the efficacy is typically even more partial (2). Moreover, GH treatment carries a risk of increased intracranial pressure (3), slipped capital femoral epiphysis (4), insulin resistance (5,6), and possibly type II diabetes mellitus (7,8). Endogenous GH excess increases the risk of colon cancer; whether or not childhood GH treatment raises cancer risk in adulthood is not known (9).…”

Section: Introductionmentioning

confidence: 99%

Human Monoclonal Antibody Fragments Targeting Matrilin-3 in Growth Plate Cartilage

et al. 2015

View full text Add to dashboard Cite

show abstract

Slipped Capital Femoral Epiphysis as a Complication of Growth Hormone Therapy

Cited by 12 publications

References 15 publications

Central precocious puberty with hypothalamic hamartoma: the first case reports of 2 siblings with different phenotypes of Seckel syndrome 5

Central precocious puberty with hypothalamic hamartoma: the first case reports of 2 siblings with different phenotypes of Seckel syndrome 5

Slipped Capital Femoral Epiphysis after 2 Months from Starting Growth Hormone Therapy

Human Monoclonal Antibody Fragments Targeting Matrilin-3 in Growth Plate Cartilage

Contact Info

Product

Resources

About